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Abstract
Background Recently it has been demonstrated that el-
evated lipoprotein (a) (LPA) levels are associated with an
increased risk of cardiovascular disease across multiple eth-
nic groups. However, there is only scanty data about the in-
cidence of elevated LPA levels in different patient cohorts.
As a consequence, we aimed to examine whether patients
with elevated LPA levels might be seen more often in a car-
diovascular center in comparison to the general population.
Methods We reviewed LPA concentrations of 52,898 con-
secutive patients who were admitted to our hospital between
January 2004 and December 2014. We subdivided them into
different groups according to their LPA levels. Data was
compared to available information in medical literature.
Results 26.4% of the patients had LPA levels >30 mg/dl
which is in line with the data from literature. Mean level of
LPA concentration in our study was twice as high in com-
parison to the general population (25.8% vs. 13.3%). 4.6%
had LPA levels >98 mg/dl (general population <0.3%).
Conclusion In patients admitted to a cardiovascular center
the proportion of LPA >30 mg/dl is comparable to the gen-
eral population but mean levels over all are twice as high
and the proportion of patients with LPA levels of >98 mg/dl
is extremely higher.
This article is part of the special issue “Lp(a) – the underestimated
cardiovascular risk factor”.
 Frank van Buuren
fvbuuren@hdz-nrw.de
1 Clinic for Cardiology, Herz- und Diabeteszentrum NRW,
Ruhr-Universität Bochum, Georgstr. 11, 32545 Bad
Oeynhausen, Germany
2 Insitute for Laboratory and Transfusion Medicine, Herz- und
Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad
Oeynhausen, Germany
Keywords Lipoprotein (a) · Cholesterol · Cardiovascular
disease · Epidemiology · Risk stratifcation
Background
Total cholesterol, high density lipoprotein (HDL), and low
density lipoprotein (LDL) are frequently used to assess the
risk of atherosclerosis due to dyslipidemia [1]. In recent
years it came evident that lipoprotein (a) (LPA) as well
is supposed to play an important role in the genesis of
atherosclerosis and thrombosis.
LPA is composed of an LDL-like particle in which
apolipoprotein B100 is covalently attached to apolipopro-
tein (a) by a disulfide bond [2, 3]. Plasma levels of LPA
are genetically determined by variation in the LPA gene
coding for apolipoprotein (a) [4]. Apolipoprotein (a) has
high structural resemblance to plasminogen [5]. Hence,
due to its composition, Erqou concluded in a meta-analysis
that there is a continuous, independent association of LPA
and the risk of coronary heart disease [6]. Furthermore,
epidemiological data suggest that elevated LPA levels
are pro-atherogenic while the exact molecular mechanism
by which LPA contributes to the atherosclerotic process
remains unclear [4, 7–10].
The incidence of LPA levels >30 mg/dl is supposed to
be between 7 and 26% in a general European population
[1, 11–13]. LPA levels >30 mg/dl are proved to be inde-
pendently associated with a three-fold risk of major ad-
verse cardiovascular events in patients after coronary artery
bypass grafting [3]. Other diseases like thromboembolism
and chronic heart failure due to impaired left ventricular
function are currently evaluated in larger patient groups
[8]. Aortic valve stenosis (AVS) is a valvular heart dis-
ease of increasing interest as its prevalence rises with age
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Table 1 Laboratory findings in 52,898 patients. Subdivision according to their LPA levels and number of individuals in the different LPA-groups
with LDL > 130 mg/dl, HDL < 40 mg/dl, HbA1c > 6.4% or creatinine > 1.29 mg/dl
LPA LDL HDL HbA1c Crea









<180 206 0.39 107 51.94 36 17.48 68 33.01 43 20.87
151–180 379 0.72 173 45.65 76 20.05 125 32.98 97 25.59
121–150 771 1.46 345 44.75 179 23.22 236 30.61 181 23.48
91–120 1635 3.09 696 42.57 365 22.32 535 32.72 315 19.27
61–90 4934 9.33 1930 39.12 1124 22.78 1930 39.12 932 18.89
31–60 6144 11.61 2219 36.12 1741 28.34 2180 35.48 1209 19.68
0–30 38,829 73.40 13127 33.81 10280 26.48 14741 37.96 6993 18.01
LPA lipoprotein (a), LDL low density lipoprotein, HDL high density lipoprotein, HbA1c glycated hemoglobin, Crea creatinine
and is estimated to affect up to 2–7% of all individuals
aged >65 years [14, 15]. The identification of risk factors
for valvular calcifications and AVS is of utmost interest
as the burden of AVS is high and often ends up in sur-
gical or catheter-based treatment like transcatheter aortic
valve implantation (TAVI) [14, 16]. In the last years it be-
came evident that AVS progression shares risk factors with
atherosclerosis. There are also hints that elevated LPA levels
contribute to an increased incidence of AVS [8]. In addi-
tion, very recent studies report on a relationship between
mitral valve stenosis and elevated LPA levels in patients
with coexisting peripheral arterial disease [17].
Next to cardiac manifestations it could be demonstrated
that elevated LPA levels are associated with extracardiac
arteriosclerosis like peripheral arterial disease and stenosis
of the arteria carotis [18, 19]. Von Depka reports about el-
evated LPA levels as an independent risk factor for venous
thromboembolism [11]. Furthermore, it has been hypoth-
esized that LPA contributes to initial wound healing but
inhibits external fibrinolysis in a later phase of the healing
process leading to its corresponding problems [20]. More-
over, a higher risk for abortions was reported in patients
with elevated LPA levels [13].
In summary, elevated LPA levels seem to predispose for
numerous non-cardiovascular and cardiovascular diseases
and all these studies thrust LPA into the limelight as it
appears to play an important role in various processes [21].
However, there is only rare data about the dispersion of
elevated LPA levels in different patient communities.
As a consequence, we aimed to examine whether pa-
tients with elevated LPA levels might be seen more often
in a cohort with cardiovascular disease in comparison to
a normal population.
Patients and methods
In a total of 52,898 consecutive patients (37.81% females,
age 61.08 ± 11.03 years) admitted to our Center between
January 2004 and December 2014 we analyzed their full
lipid profile including LPA, triglycerides, total cholesterol,
HDL, and LDL. Furthermore, we checked for diabetes mel-
litus (glycated hemoglobin = HbA1c) and renal function
(creatinine, glomerular filtration rate (GFR)). Patients were
assigned to seven different groups according to their LPA
concentrations (30 mg/dl steps and more than 180 mg/dl).
Table 1 shows the distribution of LPA concentrations in
the different groups.
Results
32.9% out of 52,898 patients had LPA levels of >20 mg/dl
(26.6% > 30 mg/dl and 18.4% >50 mg/dl correspondingly).
There was no difference in the groups according HbA1c
levels and renal function (creatinine).
Discussion
The last three decades have seen favorable trends in LDL
hypercholesterolemia most likely due to an increased
awareness in the context of cardiovascular disease and
the extended use of lipid-lowering drugs [22]. It was
demonstrated that increased circulating levels of LPA are
associated with an increased risk ofcardiovascular disease
(coronary heart disease, aortic valve stenosis etc.) and
stroke [23].
A substantial fraction of the general population has LPA
concentrations that might place them at increased risk for
cardiovascular disease [21]. Unfortunately there is only
scanty data about the incidence of increased LPA levels
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in the general population and, even more interesting, in
populations with cardiovascular disease [7].
Proportion of different elevated LPA levels in the
general population
Plasma levels of LPA are similar in men and women. Epi-
demiological studies showed that LPA concentrations are
lowest in non-Hispanic Caucasians (median 12 mg/dl), Chi-
nese (median 11 mg/dl), and Japanese (median 13) [24, 25].
On the other hand, they are supposed to be slightly higher
in Hispanics (median 19), and even higher levels can be
seen in individuals of African origin (median 39).
The typical distributions of LPA in the general Cau-
casian population can be derived from the Copenhagen
City Heart Study, in which more than 20,000 individuals
were included. In a subgroup analysis with 3000 men and
3000 women they found that 20% had LPA plasma lev-
els >50 mg/dl representing individuals above the 80th per-
centile [24]. This data is in line with our findings, where
18.4% of our individuals turned out to have LPA levels
>50 mg/dl.
Other surveys report about the incidence of LPA levels
>30 mg/dl in a general adult population in Italy [12]. In that
analysis 1195 individuals were screened and about 26% of
them had levels >30 mg/dl. This correlates to the propor-
tion of patients in our group in which 26.6% showed corre-
sponding levels. Bucci reports about LPA levels >20 mg/dl
in about 25% of a general population of Caucasian origin
[26]. In contrast, 32.9% of our patient cohort had LPA levels
>20 mg/dl indicating that elevated levels might predispose
for admission in a cardiovascular center.
Mean levels of LPA in different communities
In terms of mean LPA levels the results are markedly differ-
ent. However, the comparison to available data in literature
is difficult as our study includes patients with cardiovascu-
lar disease and not members of a general population.
Hopewell investigated the impact of elevated LPA levels
on coronary heart disease and compared his findings with
the LPA levels of a control group which was supposed to be
healthy [27]. Mean age in this group was 60.9 years, mean
LPA levels in the healthy individuals were 10.56 mg/dl. In
a general population study, Langsted found mean LPA lev-
els of 17.3 mg/dl [28] compared tos 13.3 mg/dl in a survey
performed by Bucci [26]. In contrast, mean levels were
twice as high in our patient collective (25.8 mg/dl). This
might support the hypothesis that elevated LPA levels can
predispose for cardiovascular diseases.
Extremely elevated LPA levels
The highest levels of LPA in the different general popula-
tion groups were between 98 and 217 mg/dl [26, 29]. How-
ever, these extreme concentrations were rare and in none of
the surveys higher than 1%. Our population included 2415
individuals (4.6%) with levels >98 mg/dl and 586 with lev-
els >150 mg/dl (1.1%). These findings suggest that patients
who were admitted to a cardiovascular center more often
have extremely high levels of LPA.
Up to now we cannot provide the exact diagnosis of the
patients with extreme LPA levels as this is still subject of
an ongoing analysis.
Treatment options
Up to now elevated LPA concentrations are largely resis-
tant to therapeutic interventions like drug therapy or diet
and thus the appropriate strategy in terms of acceptable
LPA levels and coexisting risk factors has been discussed
extensively. Due to their genetic disposition, LPA levels are
intraindividually stable over time.
Niacin has a potential to decrease plasma LPA levels by
approximately 20–30% [21]. However, it was withdrawn
from the market due to major side effects, mainly hepato-
toxicity and flushing.. Furthermore, two recent clinical trials
found that, despite positive effects on LPA plasma levels,
niacin failed to improve clinical outcome endpoints [30].
In particular there is no data that describes the influence of
niacin therapy on LPA levels in a large community.
Alternatively, newly developed drugs like mipomersin,
a second generation antisense oligonucleotide, reduces
plasma levels of LPA by 21–36% [31]. Moreover, PCSK9-
inhibitors, drugs that affect LPA levels by influencing the
LDL–receptor degradation, may reduce LPA levels by up
to 30%. However, neither for this therapeutic option there
are still no data available illuminating clinical endpoints
[32].
Currently, only LPA apheresis is a proved therapy to
reduce LPA levels by more than 60% per session thus hav-
ing a positive influence on the reduction of cardiovascular
events [33–37].
Conclusion
The presented data shows, as far as we know, for the first
time the incidence of elevated LPA concentrations in a large
cohort of patients in a cardiovascular center. Mean LPA
concentrations are higher and extreme LPA values are seen
more often in cardiovascular patients whereas the propor-
tion of individuals with levels >30/mg is similar in com-
parison to the general population. Against this background
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the crucial questions of correct cut-off values and the new
therapeutic options beyond apheresis therapy have to be
addressed in the upcoming years.
Limitations of the study
The study was not designed as a population-based study
because all patients are individuals who were admitted to
a cardiovascular center. Many of them were diagnosed to
suffer from cardiac disease. However, the proportion of pa-
tient in whom no relevant cardiovascular disease was found
is unknown and is still subject of ongoing analysis.
Conflict of interest F. van Buuren received honoraria for lectures from
Daiichi Sankyo, Amgen and Fresenius Medical Care and travel reim-
bursement from Biotronik. K.P. Mellwig received honoraria for lec-
tures and travel reimbursement from B. Braun and Fresenius Medical
Care. D. Horstkotte, C. Knabbe and D. Hinse declare that they have no
competing interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Scheidt-Nave C, Du Y, Knopf H, Schienkiewitz A, Ziese T,
Nowossadeck E, Goesswald A, Busch MA (2013) Prevalence
of dyslipidimia among adults in Germany. Bundesgesundheitsblatt
56:661–667
2. Berg K (1963) A new serum type system in man – the LP system.
Acta Pathol Microbiol Scand 59:369–382
3. Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky
SN (2014) Lipoprotein(a) level and apolipoprotein(a) phenotype
as predictors of long-term cardiovascular outcomes after coronary
artery bypass grafting. Atherosclerosis 235:477–482
4. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG (2013) Ex-
treme lipoprotein(a) levels and improved cardiovascular risk pre-
diction. J Am Coll Cardiol 61:1146–1156
5. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY,
Fless GM, Scanu AM, Lawn RM (1987) cDNA sequence of hu-
man apolipoprotein(a) is homologous to plasminogen. Nature
330:132–137
6. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A,
White IR, Marcovina SM, Collins R, Thompson SG, Danesh J
(2009) Lipoprotein(a) concentration and the risk of coronary heart
disease, stroke, and nonvascular mortality. JAMA 302:412–423
7. Graham MJ, Viney N, Crooke RM, Tsimikas S (2016) Antisense in-
hibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels
in humans. J Lipid Res 57:340–351
8. Nordestgaard BG, Langsted A (2016) Lipoprotein (a) as a cause of
cardiovascular disease: insights from epidemiology, genetics, and
biology. J Lipid Res 57:1953–1975
9. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG
(2008) Extreme lipoprotein(a) levels and risk of myocardial infarc-
tion in the general population: the Copenhagen City Heart Study.
Circulation 117:176–184
10. Schatton CM (2015) Lp(a) als unabhängiger Risikofaktor für eine
KHK – Eine Mached-Pair-Analyse aus 32.000 Laboruntersuchun-
gen. Dissertation, Ruhr University Bochum, Germany.
11. von Depka M, Nowak-Göttl U, Eisert R, Dieterich C, Barthels M,
Scharrer I, Ganser A, Ehrenforth S (2000) Increased lipoprotein (a)
levels as an independent risk factor for venous thromboembolism.
Blood 96:3364–3368
12. Lippi G, Targher G, Franchini M, Guidi GC (2009) Biochemical
correlates of lipoprotein(a) in a general adult population. Possible
implications for cardiovascular risk assessment. J Thromb Throm-
bolysis 27:44–47
13. Weidensee S, Demuth S, Schleußner E (2012) Häufigkeit von
erhöhten Lipoprotein(a)-Spiegeln in einem ausgewählten Patien-
tenkollektiv mit habituellen Aborten und Spätaborten. Z Geburts-
hilfe Neonatol 216:P37. doi:10.1055/s-0032-1309129
14. Arsenault BJ, Boekholdt SM, Dubé MP, Rhéaume E, Wareham
NJ, Khaw KT, Sandhu MS, Tardif JC (2014) Lipoprotein(a) lev-
els, genotype, and incident aortic valve stenosis: a prospective
mendelian randomization study and replication in a case-control
cohort. Circ Cardiovasc Genet 7:304–310
15. Hung MY, Witztum JL, Tsimikas S (2014) New therapeutic targets
for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-as-
sociated phospholipase A2-oxidized phospholipid axis. J Am Coll
Cardiol 63:478–480
16. Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T,
Seino Y, Nagoh N, Kayaba K, Yamada S, Matsuo H et al (1995)
Correlation between lipoprotein(a) and aortic valve sclerosis as-
sessed by echocardiography (the JMS Cardiac Echo and Cohort
Study). Am J Cardiol 76:928–932
17. Hojo Y, Kumakura H, Kanai H, Iwasaki T, Ichikawa S, Kurabayashi
M (2016) Lipoprotein(a) is a risk factor for aortic and mitral valvu-
lar stenosis in peripheral arterial disease. Eur Heart J Cardiovasc
Imaging 17:492–497
18. van Buuren F, Sommer JA, Kottmann T, Horstkotte D, Mellwig KP
(2015) Extracardiac manifestation of elevated lipoprotein(a) levels
– cumulative incidence of peripheral arterial disease and stenosis of
the carotid artery. Clin Res Cardiol Suppl 10:39–45
19. Imhof A, Rothenbacher D, Khuseyinova N, Hoffmeister A, Maerz
W, Nauck M, Scharnagl H, Koenig W, Brenner H (2003) Plasma
lipoprotein Lp(a), markers of haemostasis and inflammation, and
risk and severity of coronary heart disease. Eur J Cardiovasc Prev
Rehabil 10:362–370
20. Yano Y, Shimokawa K, Okada Y, Noma A (1997) Immunolocaliza-
tion of lipoprotein(a) in wounded tissues. J Histochem Cytochem
45:559–568
21. Boffa MB, Koschinsky ML (2013) Screening for and management
of elevated Lp(a). Curr Cardiol Rep 15:417
22. Cohen JD, Cziraky MJ, Cai Q, Wallace A, Wasser T, Crouse JR,
Jacobson TA (2010) 30-year trends in serum lipids among United
States adults: results from the National Health and Nutrition Exam-
ination Surveys II, III, and 1999–2006. Am J Cardiol 106:969–975
23. Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN,
Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt
SM, Sandhu MS (2012) Lipoprotein(a) and risk of coronary,
cerebrovascular, and peripheral artery disease: the EPIC-Nor-
folk prospective population study. Arterioscler Thromb Vasc Biol
32:3058–3065
24. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts
GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher
E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z,
Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A (2010) European
Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a car-
diovascular risk factor: current status. Eur Heart J 31:2844–2853
25. Forbang NI, Criqui MH, Allison MA, Ix JH, Steffen BT, Cushman
M, Tsai MY (2016) Sex and ethnic differences in the associations
K
Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease 59
between lipoprotein(a) and peripheral arterial disease in the Multi-
Ethnic Study of Atherosclerosis. J Vasc Surg 63:453–458
26. Bucci M, Tana C, Giamberardino MA, Cipollone F (2016) Lp(a)
and cardiovascular risk: Investigating the hidden side of the moon.
Nutr Metab Cardiovasc Dis 26:980–986
27. Hopewell JC, Seedorf U, Farrall M, Parish S, Kyriakou T, Goel
A, Hamsten A, Collins R, Watkins H, Clarke R, Consortium PRO-
CARDIS (2014) Impact of lipoprotein(a) levels and apolipopro-
tein(a) isoform size on risk of coronary heart disease. J Intern Med
276:260–268
28. Langsted A, Kamstrup PR, Nordestgaard BG (2014) Lipopro-
tein(a): fasting and nonfasting levels, inflammation, and cardiovas-
cular risk. Atherosclerosis 234:95–101
29. Spence JD, Koschinsky M (2012) Mechanisms of lipoprotein(a)
pathogenicity: prothrombotic, proatherosclerotic, or both? Arte-
rioscler Thromb Vasc Biol 32:1550–1551
30. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-
Nickens P, Koprowicz K, McBride R, Teo K, AIM-HIGH Investi-
gators (2011) Niacin in patients with low HDL cholesterol levels
receiving intensive statin therapy. N Engl J Med 365:2255–2267
31. Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-
Thiessen E, Tsimikas S (2015) Mipomersen, an antisense oligonu-
cleotide to apolipoprotein B-100, reduces lipoprotein(a) in various
populations with hypercholesterolemia: results of 4 phase III trials.
Arterioscler Thromb Vasc Biol 35:689–699
32. Stefanutti C, Morozzi C (2016) HyperLp(a) lipoproteinaemia: un-
met need of diagnosis and treatment? Blood Transfus 14:408–412
33. Mellwig KP, Pulawski E, Horstkotte D, van Buuren F (2012) Lipid
apheresis: oxidative stress, rheology, and vasodilatation. Clin Res
Cardiol Suppl 7:45–49
34. Mellwig KP, van Buuren F, Schmidt HK, Wielepp P, Burchert W,
Horstkotte D (2006) Improved coronary vasodilatatory capacity by
H.E.L.P. apheresis: comparing initial and chronic treatment. Ther
Apher Dial 10:510–517
35. van Buuren F, Kreickmann S, Horstkotte D, Kottmann T, Mellwig
KP (2012) HELP apheresis in hypercholesterolemia and cardiovas-
cular disease: efficacy and adverse events after 8,500 procedures.
Clin Res Cardiol Suppl 7:24–30
36. von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR,
Julius U (2013) Differences in the atherogenic risk of patients
treated by lipoprotein apheresis according to their lipid pattern.
Atheroscler Suppl 14:39–44
37. Poller WC, Dreger H, Morgera S, Berger A, Flessenkämper I,
Enke-Melzer K (2015) Lipoprotein apheresis in patients with pe-
ripheral artery disease and hyperlipoproteinemia(a). Atheroscler
Suppl 18:187–193
K
